True precision medicine
Application of the ADAC technology has the potential to enable production and delivery of cost-effective, tailored-made, synthetic peptide-based therapeutics, as a tool in the fight against cancer.
IVAs 100-lista 2022
Using our novel proprietary Adaptable Drug Affinity Conjugate (ADAC) technology, we aim to take precision medicine to a new level, enabling development of individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor.
Such a highly targeted treatment design offers the potential to increase therapeutic efficacy and reduce dosage levels thereby minimizing the risk of side effects.
Application of the ADAC technology has the potential to enable production and delivery of cost-effective, tailored-made, synthetic peptide-based therapeutics, as a tool in the fight against cancer.
